Jiangsu wuzhong(SH:600200) Zheng Quan Zhi Xing·2025-06-26 16:06Core Viewpoint - The company plans to conclude certain fundraising projects and permanently supplement working capital with the remaining funds, aiming to enhance the efficiency of fund utilization and improve operational effectiveness [1][2][3][4] Group 1: Fundraising Project Overview - As of June 16, 2025, the company has utilized 496.14 million yuan of the fundraising amount, with a remaining balance of 26.41 million yuan [1] - The company has experienced some idle funds due to the construction progress of fundraising projects, which require a certain period for investment [1] Group 2: Project Adjustments and Fund Allocation - The company has decided to terminate two sub-research projects under the "Linezolid and Voronazone Generic Project" while retaining the "Linezolid Sodium Chloride Injection" for continued development [2] - The remaining funds of 9.42 million yuan from the concluded project will be permanently allocated to supplement working capital for daily operations and business development [2][3] Group 3: Approval Process - The company's board of directors approved the proposal to conclude certain fundraising projects and allocate the remaining funds during a meeting on June 25, 2025, which will also be submitted for shareholder approval [3][4] - The supervisory board has also reviewed and approved the proposal, confirming that the project conclusion aligns with the actual construction status and does not harm the interests of shareholders [3][4] Group 4: Sponsor's Verification Opinion - The sponsor, Zhongshan Securities, has verified that the conclusion of the fundraising projects and the permanent allocation of remaining funds have been approved by the board and supervisory board, and are in compliance with relevant regulations [4]